Tetanus |
Lockjaw |
Clinical Trial: Immunogenicity and Safety of PENTAXIM™ in Indian Population
This study is not yet open for patient recruitment.
Verified by Sanofi-Aventis December 2005
|
Purpose
The present clinical study will assess the immunogenicity as primary objective and reactogenicity as secondary objective of Aventis Pasteur’s DTacP-IPV// PRP~T combined vaccine (PENTAVAC™ or PENTAXIM™) as a three-dose primary vaccination at 6, 10 and 14 weeks of age followed by a booster dose during the second year of life.
Safety:
To describe the safety after each dose of the primary series of the study combined vaccine (PENTAXIM™).
| Condition | Intervention | Phase |
|---|---|---|
| Diphtheria Tetanus Polio Pertussis Haemophilus Influenzae Type B | Vaccine: Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine | Phase III |
MedlinePlus related topics: Bacterial Infections; Bronchitis; Diphtheria; Lung Diseases; Polio and Post-Polio Syndrome; Tetanus
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Study start: January 2006
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Aged 42 to 56 days inclusive on the day of inclusion
- Born at full term pregnancy (>37 weeks) with a birth weight ≥ 2.5 kg
- Informed consent form signed by the parent(s) or other legal representative
- Able to attend all scheduled visits and to comply with all trial procedures
Exclusion Criteria:
- Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination
- Planned participation in another clinical trial during the present trial period
- Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
- Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
- Chronic illness at a stage that could interfere with trial conduct or completion.
- Blood or blood–derived products received in the past.
- Any vaccination preceding trial vaccination (except BCG)
- History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Haemophilus influenza type b (confirmed either clinically, serologically or microbiologically).
- Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B diseases or Haemophilus influenza type b infection with the trial vaccine or another vaccine.
- Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
- History of/current seizures
- Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or acute illness on the day of inclusion
Location and Contact Information
India
New Delhi, India
Clinical Trials, Study Director, sanofi pasteur
More Information
Last Updated: December 13, 2005
Record first received: November 24, 2005
ClinicalTrials.gov Identifier: NCT00259337
Health Authority: India: Indian Council of Medical Research
ClinicalTrials.gov processed this record on 2006-01-10
Resources
- ClinicalTrials.gov: Tetanus (National Institutes of Health)
- Diphtheria, Tetanus, and Pertussis Vaccines (Centers for Disease Control and Prevention) - Links to PDF File (National Immunization Program Resource Center, CDC, OPHS, HHS)

Not Signed In -

